Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Ennio Favalli and Roberto Caporali.
Ennio Favalli
Connection Strength
13.492
Roberto Caporali
  1. Clinical management of patients with rheumatoid arthritis during the COVID-19 pandemic. Expert Rev Clin Immunol. 2021 06; 17(6):561-571.
    View in: PubMed
    Score: 0.940
  2. Is there really room for anti-rheumatic drugs in the treatment of COVID-19? Scand J Rheumatol. 2020 09; 49(5):412-413.
    View in: PubMed
    Score: 0.895
  3. Role of antimalarials in COVID-19: observational data from a cohort of rheumatic patients. Ann Rheum Dis. 2021 05; 80(5):e75.
    View in: PubMed
    Score: 0.888
  4. GM-CSF in the treatment of COVID-19: a new conductor in the pathogenesis of cytokine storm? Lancet Rheumatol. 2020 Aug; 2(8):e448-e449.
    View in: PubMed
    Score: 0.887
  5. Dr. Favalli, et al reply. J Rheumatol. 2020 10 01; 47(10):1592.
    View in: PubMed
    Score: 0.885
  6. Are patients with systemic lupus erythematosus at increased risk for COVID-19? Ann Rheum Dis. 2021 02; 80(2):e25.
    View in: PubMed
    Score: 0.884
  7. Managing patients with rheumatic conditions during the covid-19 pandemic. BMJ. 2020 04 27; 369:m1633.
    View in: PubMed
    Score: 0.879
  8. Incidence and Clinical Course of COVID-19 in Patients with Connective Tissue Diseases: A Descriptive Observational Analysis. J Rheumatol. 2020 08 01; 47(8):1296.
    View in: PubMed
    Score: 0.879
  9. What is the true incidence of COVID-19 in patients with rheumatic diseases? Ann Rheum Dis. 2021 02; 80(2):e18.
    View in: PubMed
    Score: 0.878
  10. Baricitinib for COVID-19: a suitable treatment? Lancet Infect Dis. 2020 09; 20(9):1012-1013.
    View in: PubMed
    Score: 0.875
  11. COVID-19 infection and rheumatoid arthritis: Faraway, so close! Autoimmun Rev. 2020 May; 19(5):102523.
    View in: PubMed
    Score: 0.873
  12. Two-year persistence of golimumab as second-line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real-life data from the LORHEN registry. Int J Rheum Dis. 2018 Feb; 21(2):422-430.
    View in: PubMed
    Score: 0.740
  13. The management of first-line biologic therapy failures in rheumatoid arthritis: Current practice and future perspectives. Autoimmun Rev. 2017 Dec; 16(12):1185-1195.
    View in: PubMed
    Score: 0.737
  14. Ensuring tight control in patients with rheumatoid arthritis treated with targeted therapies during the COVID-19 pandemic using a telehealth strategy. Ann Rheum Dis. 2021 09; 80(9):1243-1245.
    View in: PubMed
    Score: 0.235
  15. Impact of corticosteroids and immunosuppressive therapies on symptomatic SARS-CoV-2 infection in a large cohort of patients with chronic inflammatory arthritis. Arthritis Res Ther. 2020 12 30; 22(1):290.
    View in: PubMed
    Score: 0.230
  16. Incidence of COVID-19 in Patients With Rheumatic Diseases Treated With Targeted Immunosuppressive Drugs: What Can We Learn From Observational Data? Arthritis Rheumatol. 2020 10; 72(10):1600-1606.
    View in: PubMed
    Score: 0.225
  17. Psoriasis and psoriatic arthritis: How to manage immunosuppressants in COVID-19 days. Dermatol Ther. 2020 07; 33(4):e13415.
    View in: PubMed
    Score: 0.220
  18. The profiling of axial spondyloarthritis patient candidate to a biologic therapy: Consensus from a Delphi-panel of Italian experts. Autoimmun Rev. 2018 Dec; 17(12):1251-1258.
    View in: PubMed
    Score: 0.198
  19. Switch or swap strategy in rheumatoid arthritis patients failing TNF inhibitors? Results of a modified Italian Expert Consensus. Rheumatology (Oxford). 2018 10 01; 57(57 Suppl 7):vii42-vii53.
    View in: PubMed
    Score: 0.197
  20. Comments on "Short-term reasons for withdrawal and adverse events associated with apremilast therapy for psoriasis in real-world practice compared with in clinical trials: A multicenter retrospective study". J Am Acad Dermatol. 2018 12; 79(6):e119-e120.
    View in: PubMed
    Score: 0.195
  21. Prevalence of Ankylosing Spondylitis Disease Activity Score (ASDAS) inactive disease in a cohort of patients treated with TNF-alpha inhibitors. Mod Rheumatol. 2018 May; 28(3):542-549.
    View in: PubMed
    Score: 0.183
  22. Comparison of efficacy of first- versus second-line adalimumab in patients with rheumatoid arthritis: experience of the Italian biologics registries. Clin Exp Rheumatol. 2017 Jul-Aug; 35(4):660-665.
    View in: PubMed
    Score: 0.179
  23. Factors influencing the choice of first- and second-line biologic therapy for the treatment of rheumatoid arthritis: real-life data from the Italian LORHEN Registry. Clin Rheumatol. 2017 Apr; 36(4):753-761.
    View in: PubMed
    Score: 0.175
  24. Use of rituximab in a multicentre cohort of patients with rheumatic diseases during the outbreak of novel SARS-COV-2 infection. Clin Exp Rheumatol. 2021 May-Jun; 39(3):695.
    View in: PubMed
    Score: 0.058
  25. Prevalence of COVID infections in a population of rheumatic patients from Lombardy and Marche treated with biological drugs or small molecules: A multicentre retrospective study. J Autoimmun. 2021 01; 116:102545.
    View in: PubMed
    Score: 0.057
  26. COVID-19 and what pediatric rheumatologists should know: a review from a highly affected country. Pediatr Rheumatol Online J. 2020 Apr 22; 18(1):35.
    View in: PubMed
    Score: 0.055
  27. Two-year retention rate of golimumab in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: data from the LORHEN registry. Clin Exp Rheumatol. 2017 Sep-Oct; 35(5):804-809.
    View in: PubMed
    Score: 0.045
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.